Our findings on the essential role of ACE2 in in vivo infections and of recombinant mACE2 administration and IFNγ/TNF blocking as therapeutic options provide a first glimpse of the potential of this new tool to increase our understanding of COVID-19 in vivo to foster the discovery of novel therapeutic options. The gene discussed is ACE2; the disease is infection.